Xilio Therapeutics Inc
NASDAQ:XLO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Xilio Therapeutics Inc
Net Change in Cash
Xilio Therapeutics Inc
Net Change in Cash Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Change in Cash | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
X
|
Xilio Therapeutics Inc
NASDAQ:XLO
|
Net Change in Cash
$82.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Net Change in Cash
-$295m
|
CAGR 3-Years
19%
|
CAGR 5-Years
61%
|
CAGR 10-Years
N/A
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Net Change in Cash
-$2.4B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
15%
|
CAGR 10-Years
N/A
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Net Change in Cash
-$2.8B
|
CAGR 3-Years
-99%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Net Change in Cash
$515.6m
|
CAGR 3-Years
-48%
|
CAGR 5-Years
-29%
|
CAGR 10-Years
19%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Net Change in Cash
$634.7m
|
CAGR 3-Years
42%
|
CAGR 5-Years
2%
|
CAGR 10-Years
15%
|
|
Xilio Therapeutics Inc
Glance View
Xilio Therapeutics, Inc. operates as a biotechnology company. The company is headquartered in Waltham, Massachusetts and currently employs 74 full-time employees. The company went IPO on 2021-10-22. The firm has built its geographically precise solutions (GPS) platform to rapidly engineer molecules, including cytokines and other biologics. The Company’s most advanced product candidates are in clinical development. Its XTX101 is a clinical-stage, tumor-selective anti-CTLA-4 mAb, which is designed to improve upon the therapeutic index of existing anti-CTLA-4 therapies by localizing its activity in the TME. The company initiated a Phase I/II trial to evaluate XTX101 in patients with advanced solid tumors, and enrollment is ongoing. XTX202 is an engineered form of IL-2, which is masked with a protein domain to prevent binding activity until the protein domain is cleaved off by TME-associated proteases. The company initiated a Phase I/II trial to evaluate XTX202 in patients with solid tumors.
See Also
What is Xilio Therapeutics Inc's Net Change in Cash?
Net Change in Cash
82.3m
USD
Based on the financial report for Dec 31, 2025, Xilio Therapeutics Inc's Net Change in Cash amounts to 82.3m USD.
What is Xilio Therapeutics Inc's Net Change in Cash growth rate?
Net Change in Cash CAGR 1Y
663%
Over the last year, the Net Change in Cash growth was 663%.
